🔎 Trials Near Me

Home › NCT07506616

Membrane Potential Mapping with18F-TPP

RecruitingPhase 1Healthy volunteers welcome

Who can join

Ages 21 to 80 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Willing and able to give voluntary written informed consent
* Stated willingness to comply with all study procedures and availability for the duration of the study
* In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry and hematology tests.
* If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study.

Exclusion Criteria:

* Know structural heart disease (e.g. myocardial infarction)
* Abnormal and clinically significant ECG (as determined by the Investigator or his/her designee) at screening.
* Laboratory tests with clinically significant abnormalities at screening
* Pregnancy or Lactation
* MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects/fragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist).
* Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale University PET Center.
* Subject who has current, past, or anticipated exposure to radiation in the workplace within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.
* Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol.
* Arterial Line Exclusion: Blood donation within eight weeks of the start of the study.
* Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).
* Arterial Line Exclusion: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) greater than 5msec above the upper limit of normal.
* Arterial Line Exclusion: Unable to safely discontinue or hold aspirin and other NSAID use

About the study

In this study, investigators propose to use PET imaging to study the pharmacokinetics of 18F-TPP and develop methods for imaging membrane potential (ΔΨT) in humans.

What is being tested

Sponsor: Yale University · Participants: 24 · Started: 2026-08

Contact the study team

Official record on ClinicalTrials.gov — NCT07506616

Locations in the U.S.

ConnecticutYale University PET Center, New Haven

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.